ClinicalTrials.gg
RecruitingNCT05037279EVERUpdated Mar 20, 2026

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

A Phase 3 interventional study of Bacillus Calmette-Guerin: Strain Russian BCG-I and Bacillus Calmette-Guerin: Strain TICE in Bladder Cancer, Bladder Cancer Recurrent and Neoplasm Recurrence, sponsored by Verity Pharmaceuticals Inc.. Recruiting at 6 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Verity Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms — 3 open to participants now, 8 under way, 4 of them phase 3. BCG Vaccine · Urinary Bladder Neoplasms.

Planned enrollment
3rd of 20
540 · median 112
Started
2024
the only one that year
Phase 3
7 of 20
2 open now
Registered
15th of 20
by date

Among the 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms, this one is the 3rd largest by planned enrollment, is the only one that started in 2024, is one of 7 in phase 3, and was the 15th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

3 of the 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About BCG Vaccine

BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with the exception of tuberculosis vaccination in childhood.

Read the detailed description

This study is a randomized, active control, double-blind clinical trial aimed at demonstrating non - inferiority of VERITY-BCG to OncoTICE, the current standard of care, with respect to two-year Recurrence Free Survival (RFS) rates in NMIBC BCG - naïve patients that are at high risk for recurrence (defined as >50%).

  • Recurrence will be defined as the reappearance of any of the NMIBC tumors as confirmed by cystoscopic biopsy or TURBT.
03

Conditions studied

  • Bladder Cancer
  • Bladder Cancer Recurrent
  • Neoplasm Recurrence
  • Urothelial Carcinoma Bladder
  • Urothelial Carcinoma Recurrent
  • Non-Invasive Bladder Urothelial Carcinoma

Keywords

  • Interventional
  • Non-inferiority study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female
  • 18 years and older
  • Low or high-grade NMIBC as defined by 2004 World Health Organization (WHO)/International Society of Urological Pathology (ISUP) classification and Grade 2 or 3 in the 1973 classification, diagnosed within 45 days of registration.
  • confirmed and completely resected stage Ta or T1 urothelial cell carcinoma, with or without associated carcinoma in situ (CIS), diagnosed within 45 days of registration.

    1. Patients with T1 disease must have imaging demonstrating no evidence of disease (based on MRI or CT scan) within (before or after) 90 days of registration, to confirm stage T1N0M0 disease.
    2. For patients with stage T1 disease, a repeat TURBT must be performed as per standard of care/CUA guidelines. A repeat TURBT may also be required for patients with Ta disease. Repeat TURBT must be performed within 60 days of the initial TURBT and within 45 days of registration. Pathological confirmation is required after the repeat TURBT.
  • Patients may have intermediate or high recurrence risk disease, as indicated by the probability of 2-year recurrence of ≥ 50% based on the EORTC Bladder Cancer risk calculator.
  • performance status of 0-2
  • Adequate organ and marrow function as defined below:

    • leukocytes ≥3,000/mcL
    • ≥1,500/mcL
    • ≥100,000/mcL
    • total ≤ 1.5 × institutional (ULN)
    • (SGOT)/ALT(SGPT) ≤3 × institutional ULN
    • creatinine ≤ institutional ULN OR (GFR) ≥50 mL/min/1.73 m2 unless data exists supporting safe use of BCG at lower kidney function values, no lower than 30 mL/min/1.73 m2
  • For women of involved in any sexual intercourse that could lead to pregnancy: Negative pregnancy test and willingness to use (consistent with local regulations) during 120 days after the last dose of the study treatment. Note: The use of contraceptive methods does not apply to subjects who are abstinent for at least 4 weeks before Day 1 and will continue to be abstinent from penile-vaginal intercourse 120 days after last dose of study drug treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.
  • Note: A woman of non-childbearing potential is defined as follows:

    • Has had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy);
    • Has had a cessation of menses for at least 12 months without an alternative medical cause, and a follicle-stimulating hormone (FSH) test confirming nonchildbearing potential (refer to laboratory reference ranges for confirmatory levels).
  • Male patients with female partner of childbearing potential must agree to be abstinent or practice an effective method of contraception.

Male patients must agree to refrain from donating sperm during the treatment period and for at least 120 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Presence of urothelial carcinoma involving the upper urinary tract or prostatic urethra documented by radiological imaging or , performed within 12 months of the start of treatment. Should the imaging or biopsy be performed outside the window it will be up to the physicians' discretion to re-scan/biopsy. This is considered T4 disease.
  • CIS only disease.
  • Pure squamous cell carcinoma or adenocarcinoma.
  • Presence of micropapillary components.
  • Other prior non-bladder , except for the following:

    • patients presenting with NMIBC recurrent tumor(s)
    • adequately treated basal cell or squamous cell skin cancer.
    • in situ cervical cancer.
    • adequately treated stage I or II cancer currently in complete remission, or any other cancer from which the patient has been disease free for five years.
    • patients with localized prostate cancer who are being followed by an active surveillance program are also eligible.
  • Prior intravesical BCG or intradermal BCG, within 5 years of screening, with the exception of tuberculosis vaccination in childhood.
  • Chronic administration of (>10 mg prednisone) at the time of randomization.
  • Current or planned concomitant biologic therapy, radiation therapy, hormonal therapy, chemotherapy, surgery, or other cancer therapy while on study.
  • Prior chemoradiation treatment (trimodal therapy or "TMT") for bladder cancer.
  • Currently being treated or scheduled to have treatment with any systemic or intravesical chemotherapeutic agent during the study.
  • Receiving any other agents.
  • The presence of an impaired immune response irrespective of whether this impairment is congenital or caused by disease, drugs or other therapy.
  • Known positive serology with detectable viral load.
  • Current diagnosis of AIDS
  • Presence of a urinary tract infection; treatment should be withheld until urine culture is negative and antibiotic therapy is stopped.
  • Trauma to the urinary bladder. In case of gross hematuria, therapy should be stopped or postponed until the hematuria has been successfully treated or has resolved.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to BCG vaccine.
  • Uncontrolled intercurrent illness.
  • Psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnancy: pregnant women are excluded from this study because VERITY-BCG is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with VERITY-BCG, breastfeeding should be discontinued if the mother is treated with VERITY-BCG.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    Verity-BCG

    * Bacillus Calmette-Guérin (BCG): Strain Russian BCG-I * Freeze-dried powder for bladder instillation

    Drug: Bacillus Calmette-Guerin: Strain Russian BCG-I

  • Active comparator
    OncoTICE

    * Standard of Care * Bacillus Calmette-Guérin (BCG): Strain TICE * Freeze-dried powder for bladder instillation

    Drug: Bacillus Calmette-Guerin: Strain TICE

Interventions

  • * Induction: 80 mg weekly for 6 weeks. * Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months. * Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.

    Also known as: Verity-BCG

  • * Induction: 50 mg weekly for 6 weeks. * Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months. * Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.

    Also known as: OncoTICE

06

What researchers measure

Primary outcomes

  1. Recurrence Free Survival (RFS) at 24 months

    Cumulative Recurrence Free Survival (RFS) at 24 months following 1st intravesical instillation as estimated using the Kaplan - Meier estimator of the survival function. Recurrence will be defined as the reappearance of any of the NMIBC tumors as confirmed by cystoscopic biopsy or TURBT.

    Time frame: 24 months

Secondary outcomes

  1. Recurrence Free Survival (RFS)

    Cumulative Recurrence Free Survival (RFS) at 36 months following 1st intravesical instillation as estimated using the Kaplan - Meier estimator of the survival function.

    Time frame: 36 months

  2. Progression Free Survival (PFS)

    Progression Free Survival (PFS) at 24 months as estimated using the Kaplan - Meier estimator of the survival function.

    Time frame: 24 months

  3. Progression Free Survival (PFS)

    Progression Free Survival (PFS) at 36 months as estimated using the Kaplan - Meier estimator of the survival function.

    Time frame: 36 months

  4. Overall Survival (OS)

    Overall Survival (OS) at 36 months as estimated using the Kaplan - Meier estimator of the survival function.

    Time frame: 36 months

  5. Change in Quality of Life

    Change in Quality of Life as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire for NMIBC (EORTC-QLQ-NMIBC24) and the Bladder Utility Symptom Scale (BUSS) over 36 months. The EORTC QLQ-NMIBC24 is a 24-item self-administered questionnaire that measures health-related quality of life in patients with intermediate to high-risk NMIBC. Items are ranked by the patient from 1 to 4 indicating the extent to which they have experienced those symptoms or problems. 1 = Not at All, 2 = A little, 3=Quite a bit, 4 = Very Much. High Score is equivalent to more problems, except for items on sexual function and sexual enjoyment for which a high score is interpreted as better function. The BUSS is a 10-item self-administered questionnaire that measures day to day health-related quality of life in patients with intermediate to high-risk NMIBC

    Time frame: 36 months

  6. Change in functioning and symptom status

    Change in functioning and symptom status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire for Cancer Patients (EORTC-QLQ-C30) over 36 months. The EORTC QLQ-C30 consists of 30 items and measures Health Related Quality of Life as well as presence of symptoms across all cancer types. The QLQ-C30 includes nine multi-item scales: * 5 functional scales (physical, role, cognitive, emotional, and social) * 3 symptom scales (fatigue, pain, and nausea and vomiting); * A global health and quality-of-life scale\* * Several single-item symptom measures 28 Items are ranked 1 to 4. 1 = Not at All, 2 = A little, 3=Quite a bit, 4 = Very Much. \*2 items are ranked 1 to 7. 1=Very Poor, 7 = Excellent. High score = More symptoms or worse problems \*High Score = Better overall health or Quality of life.

    Time frame: 36 months

Other outcomes

  1. Safety: Incidence of treatment-emergent AEs and SAEs

    Incidence of treatment-emergent AEs and SAEs defined according to the CTCAE v5.0;

    Time frame: 36 months

  2. Safety: Number of discontinued subjects

    Number of subjects discontinuing study drug due to AEs

    Time frame: 36

  3. Safety: concomitant medications

    Usage of concomitant medications over time.

    Time frame: 36 months

07

Study locations

4 of 6 sites recruiting
  • Site 05
    Vancouver, British Columbia, Canada
    Recruiting
    • Principal Investigator · Contact
  • Site 04
    Kingston, Ontario, Canada
    Recruiting
    • Principal Investigator · Contact
  • Site 01
    Toronto, Ontario, Canada
    Recruiting
    • Principal Investigator · Contact
  • Site 02
    Toronto, Ontario, Canada
    Not yet recruiting
    • Principal Investigator · Contact
  • Site 08
    Toronto, Ontario, Canada
    Recruiting
  • Site 10
    Montreal, Quebec, Canada
    Not yet recruiting
    • Principal Investigator · Contact
08

References and documents

Individual participant data

Plan to share: No — Participants will only be identified by a code number. Sponsor may share anonymized study data with their commercial partners. All parties will respect the confidentiality rules in effect.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Feb 2029, 58 months after the start.

Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's planned 58 months is close to that.

Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2021
First posted
Sep 8, 2021
StartActual
Apr 24, 2024
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05037279
Lead sponsor
Verity Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Sep 8, 2021
Start date
Apr 24, 2024
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Mar 20, 2026

Study contacts

Taniya Mann, PhD, MBA
Contact
medinfo@veritypharma.com
800-977-9778
Girish S Kulkarni, MD
principal investigator · Princess Margaret Cancer Centre, 700 University Ave, 6-824 Toronto, ON, M5G 1X6, Canada
Alexandre R Zlotta, MD, PhD, FRCSC
principal investigator · Mount Sinai Hospital, 600 University Avenue, Toronto, ON, M5G 1X5

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BCG Vaccine

Start the discussion